Is Tepotinib (Tuodekang) a targeted drug and analysis of its mechanism of action

Tepotinib (Tepotinib) is an oral small molecule targeted drug, mainly used to treat METgene exon 14 skipping mutation (MET exon 14 skipping mutation)-positive non-small cell lung cancer (NSCLC) patients. As a targeted therapy drug, Tepotinib can selectively recognize and inhibit the activity of MET tyrosine kinase, thereby blocking the proliferation, migration and survival signals of tumor cells. This property makes it highly effective in MET-driven tumors while causing fewer side effects on normal tissues than traditional chemotherapy drugs.

In terms of its mechanism of action, tepotinib binds to the ATP binding pocket of the MET receptor, inhibiting its tyrosine kinase activity and blocking downstream< /span>RAS/MAPK, PI3K/AKT and STAT and other signaling pathways. METGene exon 14 skipping mutations will block the degradation of MET receptors, activate abnormal signaling pathways, and promote tumor growth and metastasis. By inhibiting this abnormal activation, Tepotinib effectively reduces tumor cell proliferation and induces apoptosis, targeting the core driving factors of the disease at the molecular level.

The targeting properties of Tepotinib are also reflected in its selective inhibition of normal cells. Because it mainly acts on abnormally activated MET signals and has less inhibition on wild-type MET receptors or unrelated signaling pathways, patients are relatively well tolerated during medication. This also enables tepotinib to be used as a long-term maintenance treatment to provide sustained disease control for patients with MET mutations. In clinical practice, tepotinib has shown a high overall response rate (ORR) and disease control rate (DCR), significantly improving the treatment prognosis of patients.

In addition, Tepotinib has also explored combination treatment strategies in its research and development and clinical application. Studies have shown that tepotinib can be used in combination with immune checkpoint inhibitors or other targeted drugs to enhance efficacy or delay the occurrence of drug resistance. Through precise targetingMETMutations and reasonable combination regimens, Tepotinib plays an important role in the personalized treatment of non-small cell lung cancer, providing new treatment options for patients with MET-driven tumors and becoming one of the important drugs in the field of targeted therapy.

Reference link:https://www.drugs.com